A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

5,500

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Influenza
Interventions
COMBINATION_PRODUCT

CD388 Injection

CD388 liquid for injection

COMBINATION_PRODUCT

Placebo

Placebo to match

Trial Locations (15)

11226

Brooklyn Clinical Research, Brooklyn

16635

Altoona Center for Clinical Research, Duncansville

19107

DM Clinical Research, Philadelphia

23226

Clinical Research Partners, LLC, Richmond

28557

West Clinical Research, Inc., Morehead City

29303

Spartanburg Medical Research, Spartanburg

29607

Tribe Clinical Research, LLC, Greenville

33135

South Florida Research Center, Inc., Miami

33161

Healthcare Clinical Data, Inc., North Miami

33435

Imagine Research - Palm Beach County, Boynton Beach

36207

Pinnacle Research Group, LLC, Anniston

44122

Velocity Clinical Research - Cleveland, Beachwood

45246

Velocity Clinical Research - Springdale, Cincinnati

68134

Velocity Clinical Research - Omaha, Omaha

06905

Stamford Therapeutics Consortium, Stamford

Sponsors
All Listed Sponsors
lead

Cidara Therapeutics Inc.

INDUSTRY

NCT07159763 - A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza | Biotech Hunter | Biotech Hunter